JP2020505322A - 局所用デトミジン製剤 - Google Patents

局所用デトミジン製剤 Download PDF

Info

Publication number
JP2020505322A
JP2020505322A JP2019531615A JP2019531615A JP2020505322A JP 2020505322 A JP2020505322 A JP 2020505322A JP 2019531615 A JP2019531615 A JP 2019531615A JP 2019531615 A JP2019531615 A JP 2019531615A JP 2020505322 A JP2020505322 A JP 2020505322A
Authority
JP
Japan
Prior art keywords
formulation
detomidine
topical
salt
human subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019531615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505322A5 (enExample
Inventor
ツィポーリ、オマー
ザマンスキー、マーク
Original Assignee
クレキシオ バイオサイエンシーズ エルティーディー．
クレキシオ バイオサイエンシーズ エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クレキシオ バイオサイエンシーズ エルティーディー．, クレキシオ バイオサイエンシーズ エルティーディー． filed Critical クレキシオ バイオサイエンシーズ エルティーディー．
Publication of JP2020505322A publication Critical patent/JP2020505322A/ja
Publication of JP2020505322A5 publication Critical patent/JP2020505322A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019531615A 2017-01-06 2018-01-05 局所用デトミジン製剤 Pending JP2020505322A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443174P 2017-01-06 2017-01-06
US62/443,174 2017-01-06
PCT/US2018/012579 WO2018129313A1 (en) 2017-01-06 2018-01-05 Topical detomidine formulations

Publications (2)

Publication Number Publication Date
JP2020505322A true JP2020505322A (ja) 2020-02-20
JP2020505322A5 JP2020505322A5 (enExample) 2021-01-14

Family

ID=61054537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531615A Pending JP2020505322A (ja) 2017-01-06 2018-01-05 局所用デトミジン製剤

Country Status (15)

Country Link
US (2) US20190343805A1 (enExample)
EP (1) EP3565526B1 (enExample)
JP (1) JP2020505322A (enExample)
KR (1) KR20190110561A (enExample)
CN (1) CN110114059A (enExample)
AU (1) AU2018205217B2 (enExample)
BR (1) BR112019011961A2 (enExample)
CA (1) CA3049389A1 (enExample)
DK (1) DK3565526T3 (enExample)
ES (1) ES2982022T3 (enExample)
HU (1) HUE068070T2 (enExample)
IL (1) IL266448B2 (enExample)
MX (1) MX382949B (enExample)
PL (1) PL3565526T3 (enExample)
WO (1) WO2018129313A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020012415A2 (en) * 2018-07-11 2020-01-16 Clexio Biosciences Ltd. Topical detomidine formulations
WO2020016827A1 (en) * 2018-07-18 2020-01-23 Clexio Biosciences Ltd. Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052347A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Transmucosale und transdermale arzneimittel mit verbesserter wirkstoffresorption
JP2008519012A (ja) * 2004-11-05 2008-06-05 オリオン コーポレーション デトミジンを含む経粘膜動物用組成物
JP2016522195A (ja) * 2013-05-17 2016-07-28 セントレキション・セラピューティクス・コーポレーションＣｅｎｔｒｅｘｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ 新規な（シアノ−ジメチル−メチル）−イソオキサゾール及び−［１，３，４］チアジアゾール
JP2016528165A (ja) * 2013-08-22 2016-09-15 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 神経障害性疼痛の処置方法
JP2016529256A (ja) * 2013-08-14 2016-09-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛を制御するための組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127586A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Topical treatments for pain
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052347A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Transmucosale und transdermale arzneimittel mit verbesserter wirkstoffresorption
JP2008519012A (ja) * 2004-11-05 2008-06-05 オリオン コーポレーション デトミジンを含む経粘膜動物用組成物
JP2016522195A (ja) * 2013-05-17 2016-07-28 セントレキション・セラピューティクス・コーポレーションＣｅｎｔｒｅｘｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ 新規な（シアノ−ジメチル−メチル）−イソオキサゾール及び−［１，３，４］チアジアゾール
JP2016529256A (ja) * 2013-08-14 2016-09-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛を制御するための組成物及び方法
JP2016528165A (ja) * 2013-08-22 2016-09-15 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 神経障害性疼痛の処置方法

Also Published As

Publication number Publication date
WO2018129313A1 (en) 2018-07-12
IL266448A (en) 2019-06-30
MX382949B (es) 2025-03-13
ES2982022T3 (es) 2024-10-14
AU2018205217B2 (en) 2023-11-09
US20230172909A1 (en) 2023-06-08
IL266448B1 (en) 2023-07-01
EP3565526B1 (en) 2024-04-17
MX2019008115A (es) 2019-10-24
CN110114059A (zh) 2019-08-09
US20190343805A1 (en) 2019-11-14
EP3565526A1 (en) 2019-11-13
CA3049389A1 (en) 2018-07-12
IL266448B2 (en) 2023-11-01
PL3565526T3 (pl) 2024-09-09
BR112019011961A2 (pt) 2019-11-05
AU2018205217A1 (en) 2019-05-23
KR20190110561A (ko) 2019-09-30
DK3565526T3 (en) 2024-05-13
HUE068070T2 (hu) 2024-12-28

Similar Documents

Publication Publication Date Title
US10179159B2 (en) Topical anesthetic formulation
US20230172909A1 (en) Topical detomidine formulations
DK1890732T3 (en) TOPICAL VASO CONSTRUCTOR PREPARATIONS AND METHODS FOR PROTECTING CELLS UNDER CANCER THERAPY AND RADIATION THERAPY
US8609722B2 (en) Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine
JP2009542657A (ja) ゲルの形態でのロピニロール含有薬学的組成物、その使用
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
US20180369136A1 (en) Devices and methods for transdermal treatment of basal cell carcinoma
US20040131665A1 (en) Topical anesthetic formulation
KR20080042769A (ko) 구역에 대한 경피 방법 및 패치
CN107921137A (zh) 组合物和治疗方法
CN105377355A (zh) 治疗甲单元的感染、疾病或病症的方法
JP2024507266A (ja) ヒドロゲル組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用
US11400061B2 (en) Onychomycosis treatment compositions and methods
US20110045096A1 (en) Solubilized delivery system for topical anesthetics
US20220305076A1 (en) Topical cyclosporine for treating psoriasis and other ailments
HK40079610B (zh) 治疗甲癣的组合物和方法
HK40079610A (zh) 治疗甲癣的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221017

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221018

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221202

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240520